Barrett's esophagus is a condition in which there is an abnormal (metaplastic) change in the mucosal cells lining the lower portion of the esophagus, from normal stratified squamous epithelium to simple columnar epithelium with interspersed goblet cells that are normally present only in the small intestine, and large intestine. This change is considered to be a premalignant condition because it is associated with a high incidence of further transition to esophageal adenocarcinoma, an often-deadly cancer.

The main cause of Barrett's esophagus is thought to be an adaptation to chronic acid exposure from reflux esophagitis. Barrett's esophagus is diagnosed by endoscopy: observing the characteristic appearance of this condition by direct inspection of the lower esophagus; followed by microscopic examination of tissue from the affected area obtained from biopsy. The cells of Barrett's esophagus are classified into four categories: nondysplastic, low-grade dysplasia, high-grade dysplasia, and frank carcinoma. High-grade dysplasia and early stages of adenocarcinoma may be treated by endoscopic resection or radiofrequency ablation. Later stages of adenocarcinoma may be treated with surgical resection or palliation. Those with nondysplastic or low-grade dysplasia are managed by annual observation with endoscopy, or treatment with radiofrequency ablation. In high-grade dysplasia, the risk of developing cancer might be at 10% per patient-year or greater.

Both macroscopic (from endoscopy) and microscopic positive findings are required to make a diagnosis. Barrett's esophagus is marked by the presence of columnar epithelia in the lower esophagus, replacing the normal squamous cell epithelium—an example of metaplasia. The secretory columnar epithelium may be more able to withstand the erosive action of the gastric secretions; however, this metaplasia confers an increased risk of adenocarcinoma.

The relative risk of esophageal adenocarcinoma is approximately 10 in those with Barrett's esophagus, compared to the general population. Most patients with esophageal carcinoma survive less than one year.

Journal of Inflammatory Bowel Diseases & Disorders brings articles in all areas related to inflammatory bowel disease, inflammatory bowel disease treatment, abdominal pain, collagenous colitis, lymphocytic colitis, diversion colitis, colon cancer, colon failure, colon disorders, intestinal endometria, bowel endometriasis, crohn's disease, celiac disease, bowel cancer, etc.

It’s our privilege to recite you as a foremost strategist in the realm of research and invite to endowment your research penmanship to write (volume 6 issue 3) Short Communication or mini review on above topic to be published in our journal.

Our Journal follows Editorial Tracking System for quality in peer review process. Editorial Tracking is an online manuscript submission, review and tracking systems used by most of the best open access journals.

Submit manuscripts at: https://www.scholarscentral.org/submissions/inflammatory-bowel-diseases-disorders.html

Media Person

Mercedes Rose
Journal Coordinator
Journal of Inflammatory Bowel Diseases and Disorders
ISSN: 2476-1958

Email: jibdd@emedsci.com